Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bioventus (BVS) Gross Margin (2020 - 2025)

Bioventus' Gross Margin history spans 6 years, with the latest figure at 68.89% for Q4 2025.

  • For Q4 2025, Gross Margin rose 208.0% year-over-year to 68.89%; the TTM value through Dec 2025 reached 68.33%, up 61.0%, while the annual FY2025 figure was 68.33%, 61.0% up from the prior year.
  • Gross Margin reached 68.89% in Q4 2025 per BVS's latest filing, up from 67.96% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 72.83% in Q2 2021 to a low of 58.96% in Q4 2022.
  • Average Gross Margin over 5 years is 67.02%, with a median of 67.31% recorded in 2021.
  • Peak YoY movement for Gross Margin: tumbled -834bps in 2022, then skyrocketed 618bps in 2024.
  • A 5-year view of Gross Margin shows it stood at 67.3% in 2021, then decreased by -12bps to 58.96% in 2022, then rose by 8bps to 63.73% in 2023, then increased by 5bps to 66.82% in 2024, then rose by 3bps to 68.89% in 2025.
  • Per Business Quant, the three most recent readings for BVS's Gross Margin are 68.89% (Q4 2025), 67.96% (Q3 2025), and 69.14% (Q2 2025).